|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:clinicalTrials.gov_Identifier
|
NCT02675114
|
|
gptkbp:conditionStudied
|
severe aortic stenosis
|
|
gptkbp:deviceUsed
|
SAPIEN 3 valve
|
|
gptkbp:foundIn
|
TAVR was noninferior to surgery for the primary endpoint at 1 year
TAVR had lower rates of death, stroke, or rehospitalization at 1 year compared to surgery
|
|
gptkbp:fullName
|
Placement of Aortic Transcatheter Valves 3 trial
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PARTNER 3 trial
|
|
gptkbp:location
|
gptkb:Canada
gptkb:Europe
gptkb:United_States
|
|
gptkbp:participants
|
1000+
|
|
gptkbp:patientPopulation
|
low surgical risk patients
|
|
gptkbp:period
|
Phase 3
|
|
gptkbp:principalInvestigator
|
gptkb:Martin_B._Leon
|
|
gptkbp:publicationYear
|
2019
|
|
gptkbp:publishedIn
|
gptkb:New_England_Journal_of_Medicine
|
|
gptkbp:result
|
composite of death, stroke, or rehospitalization at 1 year
|
|
gptkbp:sponsor
|
gptkb:Edwards_Lifesciences
|
|
gptkbp:startYear
|
2016
|
|
gptkbp:studiedIntervention
|
transcatheter aortic valve replacement
surgical aortic valve replacement
|
|
gptkbp:bfsParent
|
gptkb:PARTNER_trial
|
|
gptkbp:bfsLayer
|
8
|